A2B 腺受体信号传递和调节
Zhan-Guo Gao1, Mansour Haddad2, Kenneth A Jacobson3
1Molecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD, 20892, USA. zg21o@nih.gov.
Purinergic signalling
|June 4, 2024
概括
A2B腺受体 (A2B R) 在炎症和疾病中起着复杂的作用. 研究强调了其通过蛋白激酶C (PKC) 的激活以及在癌症和喘中潜在的治疗向.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- A2B腺受体 (A2B R) 是一种由腺激活的G蛋白合受体.
- 蛋白激酶C (PKC) 也激活A2B R,它在包括癌细胞和光滑肌肉细胞在内的各种细胞类型中表达.
- A2B R信号与喘,癌症,糖尿病和炎症有关,具有双重的亲和抗炎作用.
研究的目的:
- 总结A2B腺受体 (A2B R) 在各种生理和病理过程中的多方面的作用.
- 要突出蛋白激酶C (PKC) 在A2B R激活和信号传递中的参与.
- 讨论A2B R调制的治疗潜力和当前研究方向.
主要方法:
- 关于A2B腺受体 (A2B R) 功能和信号传导的研究文献综述.
- 在不同细胞类型和疾病模型中分析A2B R表达.
- 检查A2B R,蛋白激酶C (PKC) 和其他信号通路之间的相互作用.
主要成果:
- A2B R在许多细胞类型和组织中得到表达,有助于各种功能.
- A2B R表现出取决于环境的益和抗炎作用,影响细胞因子分泌.
- A2B R和PKC都在心脏保护中发挥作用,它们的信号传递可以被抗剂抑制.
- 抑制PKC和A2B R的抑制剂正在进行癌症治疗的临床研究.
- 像硫福拉这样的天然化合物可以通过与特定的氨酸残留物相互作用来抑制A2B R信号传递.
结论:
- A2B腺受体 (A2B R) 是癌症,喘和心血管疾病等疾病治疗干预的重要点.
- 了解A2B R的复杂信号传递,包括它与PKC的相互作用,对于开发有效的治疗方法至关重要.
- 需要进一步的研究,包括选择性激动剂的开发,以充分阐明A2B R的作用和优化治疗策略.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Receptors (Adrenoceptors): Classification
2.5K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.5K
Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
736
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
736
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
727
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
727
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


